- Home
- INMB vs VTYX Comparison
INMB vs VTYX Comparison
Compare INMB & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- VTYX
- Stock Information
- Founded
- INMB 2015
- VTYX 2018
- Country
- INMB United States
- VTYX United States
- Employees
- INMB N/A
- VTYX N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- INMB Health Care
- VTYX Health Care
- Exchange
- INMB Nasdaq
- VTYX Nasdaq
- Market Cap
- INMB 176.5M
- VTYX 154.9M
- IPO Year
- INMB 2019
- VTYX 2021
- Fundamental
- Price
- INMB $7.44
- VTYX $1.72
- Analyst Decision
- INMB Strong Buy
- VTYX Buy
- Analyst Count
- INMB 3
- VTYX 4
- Target Price
- INMB $24.33
- VTYX $11.33
- AVG Volume (30 Days)
- INMB 274.4K
- VTYX 1.5M
- Earning Date
- INMB 05-08-2025
- VTYX 05-08-2025
- Dividend Yield
- INMB N/A
- VTYX N/A
- EPS Growth
- INMB N/A
- VTYX N/A
- EPS
- INMB N/A
- VTYX N/A
- Revenue
- INMB $50,000.00
- VTYX N/A
- Revenue This Year
- INMB N/A
- VTYX N/A
- Revenue Next Year
- INMB $43,178.43
- VTYX N/A
- P/E Ratio
- INMB N/A
- VTYX N/A
- Revenue Growth
- INMB N/A
- VTYX N/A
- 52 Week Low
- INMB $4.32
- VTYX $0.78
- 52 Week High
- INMB $10.50
- VTYX $5.66
- Technical
- Relative Strength Index (RSI)
- INMB 48.52
- VTYX 62.71
- Support Level
- INMB $7.15
- VTYX $1.65
- Resistance Level
- INMB $8.06
- VTYX $1.85
- Average True Range (ATR)
- INMB 0.45
- VTYX 0.15
- MACD
- INMB -0.01
- VTYX 0.03
- Stochastic Oscillator
- INMB 27.62
- VTYX 69.32
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.